Ankylosing spondylitis medical therapy: Difference between revisions
Jump to navigation
Jump to search
| Line 7: | Line 7: | ||
==Medical Therapy== | ==Medical Therapy== | ||
* Medical therapy for AS is according to the guidelines proposed by <ref name="pmid21540199">{{cite journal |vauthors=Braun J, van den Berg R, Baraliakos X, Boehm H, Burgos-Vargas R, Collantes-Estevez E, Dagfinrud H, Dijkmans B, Dougados M, Emery P, Geher P, Hammoudeh M, Inman RD, Jongkees M, Khan MA, Kiltz U, Kvien T, Leirisalo-Repo M, Maksymowych WP, Olivieri I, Pavelka K, Sieper J, Stanislawska-Biernat E, Wendling D, Ozgocmen S, van Drogen C, van Royen B, van der Heijde D |title=2010 update of the ASAS/EULAR recommendations for the management of ankylosing spondylitis |journal=Ann. Rheum. Dis. |volume=70 |issue=6 |pages=896–904 |date=June 2011 |pmid=21540199 |pmc=3086052 |doi=10.1136/ard.2011.151027 |url=}}</ref> | * Medical therapy for AS is according to the guidelines proposed by <ref name="pmid21540199">{{cite journal |vauthors=Braun J, van den Berg R, Baraliakos X, Boehm H, Burgos-Vargas R, Collantes-Estevez E, Dagfinrud H, Dijkmans B, Dougados M, Emery P, Geher P, Hammoudeh M, Inman RD, Jongkees M, Khan MA, Kiltz U, Kvien T, Leirisalo-Repo M, Maksymowych WP, Olivieri I, Pavelka K, Sieper J, Stanislawska-Biernat E, Wendling D, Ozgocmen S, van Drogen C, van Royen B, van der Heijde D |title=2010 update of the ASAS/EULAR recommendations for the management of ankylosing spondylitis |journal=Ann. Rheum. Dis. |volume=70 |issue=6 |pages=896–904 |date=June 2011 |pmid=21540199 |pmc=3086052 |doi=10.1136/ard.2011.151027 |url=}}</ref><ref name="pmid16126791">{{cite journal |vauthors=Zochling J, van der Heijde D, Burgos-Vargas R, Collantes E, Davis JC, Dijkmans B, Dougados M, Géher P, Inman RD, Khan MA, Kvien TK, Leirisalo-Repo M, Olivieri I, Pavelka K, Sieper J, Stucki G, Sturrock RD, van der Linden S, Wendling D, Böhm H, van Royen BJ, Braun J |title=ASAS/EULAR recommendations for the management of ankylosing spondylitis |journal=Ann. Rheum. Dis. |volume=65 |issue=4 |pages=442–52 |date=April 2006 |pmid=16126791 |pmc=1798102 |doi=10.1136/ard.2005.041137 |url=}}</ref> | ||
** Assessment of SpondyloArthritis international Society (ASAS) | ** Assessment of SpondyloArthritis international Society (ASAS) | ||
** European League Against Rheumatism (EULAR) | ** European League Against Rheumatism (EULAR) | ||
Revision as of 19:10, 31 March 2018
|
Ankylosing spondylitis Microchapters |
|
Diagnosis |
|---|
|
Treatment |
|
Case Studies |
|
Ankylosing spondylitis medical therapy On the Web |
|
American Roentgen Ray Society Images of Ankylosing spondylitis medical therapy |
|
Risk calculators and risk factors for Ankylosing spondylitis medical therapy |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]
Overview
Pharmacologic medical therapies for ankylosing spondylitis(AS) include Nonsteroidal anti-inflammatory drugs (NSAIDs), tumor necrosis factor (TNF) blocker, and interleukin 17 (IL-17) inhibitors.Ankylosing spondylitis (AS) is a chronic inflammatory disease which is manifested by back pain and gradually to spinal stiffness.While treating the AS patients the primary goal is to maximize long-term health-related quality of life.
Medical Therapy
- Medical therapy for AS is according to the guidelines proposed by [1][2]
- Assessment of SpondyloArthritis international Society (ASAS)
- European League Against Rheumatism (EULAR)
- American College of Rheumatology (ACR)/Spondylitis Association of America (SAA)/Spondyloarthritis Research and Treatment Network (SPARTAN) collaboration
- Pharmacologic medical therapies for ankylosing spondylitis(AS) include Nonsteroidal anti-inflammatory drugs (NSAIDs), tumor necrosis factor (TNF) blocker, and interleukin 17 (IL-17) inhibitors.
References
- ↑ Braun J, van den Berg R, Baraliakos X, Boehm H, Burgos-Vargas R, Collantes-Estevez E, Dagfinrud H, Dijkmans B, Dougados M, Emery P, Geher P, Hammoudeh M, Inman RD, Jongkees M, Khan MA, Kiltz U, Kvien T, Leirisalo-Repo M, Maksymowych WP, Olivieri I, Pavelka K, Sieper J, Stanislawska-Biernat E, Wendling D, Ozgocmen S, van Drogen C, van Royen B, van der Heijde D (June 2011). "2010 update of the ASAS/EULAR recommendations for the management of ankylosing spondylitis". Ann. Rheum. Dis. 70 (6): 896–904. doi:10.1136/ard.2011.151027. PMC 3086052. PMID 21540199.
- ↑ Zochling J, van der Heijde D, Burgos-Vargas R, Collantes E, Davis JC, Dijkmans B, Dougados M, Géher P, Inman RD, Khan MA, Kvien TK, Leirisalo-Repo M, Olivieri I, Pavelka K, Sieper J, Stucki G, Sturrock RD, van der Linden S, Wendling D, Böhm H, van Royen BJ, Braun J (April 2006). "ASAS/EULAR recommendations for the management of ankylosing spondylitis". Ann. Rheum. Dis. 65 (4): 442–52. doi:10.1136/ard.2005.041137. PMC 1798102. PMID 16126791.